Health Care·Health Care Equipment·$158.4B
Abbott Labs (ABT) is a global health care company that develops medical devices, diagnostics, and nutrition products. With a market cap of $167 billion, it plays a crucial role in health care innovation, especially in areas like diabetes management and heart health.
EPS (Earnings Per Share)
EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
While specific revenue estimates are not available, growth in revenue is critical for assessing Abbott's market position and demand for its products.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+1.05%
Avg Stock Reaction
-3.34%
In Q1 2026, Abbott reported an EPS of $1.15, slightly beating expectations. However, the stock dropped 6% the following day, indicating market skepticism despite the earnings beat.
Management Promises & Guidance
Overall expectations for Abbott's upcoming earnings are mixed, given its history of beating EPS estimates but experiencing stock declines afterward.
Bull Case
Optimistically, if Abbott continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence.
Bear Case
Conversely, if the stock reacts negatively again despite a beat, it may indicate deeper concerns about revenue growth or market conditions.
EPS (Earnings Per Share)
N/AEPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/AWhile specific revenue estimates are not available, growth in revenue is critical for assessing Abbott's market position and demand for its products.
Market Reaction to Earnings
N/AUnderstanding how the stock has reacted historically to earnings surprises can provide insight into potential volatility post-report.
The print will turn on these two things.
Q1
What will be the EPS for Q2-2026?
Given Abbott's history of beating EPS estimates, the actual EPS figure will be crucial in determining market sentiment and stock performance.
Q2
How is Abbott addressing revenue growth challenges?
Investors will be keen to hear about strategies to drive revenue, especially in light of recent stock declines despite earnings beats.
Why consensus could be wrong
The consensus may underestimate Abbott's ability to innovate and capture market share, particularly in emerging health care segments.
Supporting Evidence
Abbott has consistently beaten EPS estimates, indicating stronger than expected operational performance.
The company's focus on diabetes care and heart health could drive future growth, despite current market skepticism.
Key Risk
If Abbott demonstrates significant revenue growth in its key segments, it could challenge the prevailing bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is under scrutiny as Abbott has consistently beaten EPS estimates but failed to sustain stock price increases.
Bull Confirmed If
An EPS of $1.20 or higher would confirm strong operational performance and potentially boost investor confidence.
Bear Confirmed If
An EPS below $1.10 would raise concerns about Abbott's growth trajectory and could lead to further stock declines.
Implied Move
±N/A
Historical Avg
±4.6%
There is no options market data available to gauge investor sentiment ahead of the earnings report.
Options are pricing ±14.8% while ABT has averaged ±4.6% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Abbott beats expectations and raises guidance, history suggests a potential average move of -3.34% the following day, indicating a cautious market reaction.
In-Line / Cautious
If results are in line with expectations but management's commentary is cautious, the stock may see limited movement as investors digest the news.
Miss
Should Abbott miss expectations, history suggests a potential average drop of -3.34%, reflecting investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
GOLDMAN SACHS GROUP
Jul 14, 2026